You are here

  • Home
  • Archive
  • Volume 32, Issue 1
  • ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma

Article metrics

Article menu
Download PDFPDF
Clinical trial
ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma

 

Online download statistics by month:

Online download statistics by month: October 2021 to April 2024

AbstractFullPdf
Oct 202135521
Nov 20218521714
Dec 2021432910
Jan 20229922519
Feb 202215251413
Mar 2022249135
Apr 202218756
May 2022246811
Jun 2022374138
Jul 202222694
Aug 202215252
Sep 202219756
Oct 202219696
Nov 202215963
Dec 202213233
Jan 202313900
Feb 202319682
Mar 202311851
Apr 202315833
May 202317624
Jun 202312737
Jul 20239710
Aug 20237621
Sep 202317424
Oct 202329287
Nov 202314252
Dec 202313871
Jan 202424551
Feb 202413572
Mar 2024214159
Apr 20247740
Total8778220155